This study compared clinical features and protein expression profiles in differentiated thyroid tumours to identify protein markers with the potential for indicating malignancy status. Tissue microarrays were constructed using 119 thyroid tumour samples (45 papillary carcinomas, 26 follicular carcinomas, 48 adenomas). Generally, there was overexpression of proliferating cell nuclear antigen (PCNA), p53, matrix metalloproteinase (MMP)-7, Hector Battifora mesothelial-1 (HBME-1), MMP-2, pituitary tumour-transforming gene (PTTG) and human telomerase reverse transcriptase (hTERT) in malignant thyroid carcinomas, and overexpression of fragile histidine triad (FHIT), p16 and E-cadherin in thyroid adenomas. Multiple factor binary logistic regression analysis indicated that MMP-2, HBME-1, p16 and FHIT were independently related to differentiated thyroid tumours. Receiveroperating characteristics for these four factors showed HBME-1 as best for diagnostic accuracy. Sensitivity and specificity were enhanced using an HBME-1 and p16 cluster. HBME-1 expression was not significantly different for papillary and follicular carcinomas, whereas p16 expression was significantly specific.
Di LoretoCTellGPestrinM: PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett2005; 224: 105–109.
4.
PavelićKDedivitisRAKapitanovićS: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutat Res2006; 599: 45–57.
5.
MarK ChoEimotoTTateyamaH: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology2006; 48: 286–294.
6.
ZhangHBuHChenH: Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: Immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol2008; 16: 32–39.
7.
LonardoFCubillaALKlimstraDS: Microadenocarcinoma of the pancreas—morphologic pattern or pathologic entity? A reevaluation of the original series. Am J Surg Pathol1996; 20: 1385–1393.
8.
CappelloFPalmaAMartoranaA: Biological aggressiveness evaluation in prostate carcinomas: Immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3 + 3) adenocarcinomas. Eur J Histochem2003; 47: 129–132.
9.
LiuYYMorreauHKievitJ: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-σ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol2008; 158: 375–384.
10.
ParkYJKwakSHKimDC: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27kip1 in the differential diagnosis of thyroid nodules. J Korean Med Sci2007; 22: 621–628.
11.
VolanteMCroceSPecchioniC: E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumor. Mod Pathol2002; 15: 1038–1043.
12.
CzyzWJoensuuHPylkkanenL: p53 protein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland. J Pathol1994; 174: 267–274.
13.
Ferreira-SilvaVRodriguesACHirataTD: Effects of 15-deoxy-Δ12, 14 prostaglandin J2 and ciglitazone on human cancer cell cycle progression and death: The role of PPARσ. Eur J Pharmacol2008; 580: 80–86.
14.
LinYCDiccianniMBKimY: Human p16σ, a novel transcriptional variant of p16INK4A, coexpresses with p16INK4A in cancer cells and inhibits cell-cycle progression. Oncogene2007; 26: 7017–7027.
15.
IshiiHWangYHuebnerK: A Fhiting role in the DNA damage checkpoint response. Cell Cycle2007; 6: 1044–1048.
16.
ZafonCObiolsGCastellvíJ: Expression of p21cip1, p27kip1, and p16INk4a cyclindependent kinase inhibitors in papillary thyroid carcinoma: Correlation with clinicopathological factors. Endocr Pathol2008; 19: 184–189.
17.
PizziSAzzoniCBassiD: Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer2003; 98: 1273–1282.
18.
MuşatMVaxVVBorboliN: Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res2004; 32: 34–62.
19.
Marie-EgyptienneDTBraultMEZhuS: Telomerase inhibition in a mouse cell line with long telomeres leads to rapid telomerase reactivation. Exp Cell Res2008; 314: 668–675.
20.
ZhaoYMLiJYLanJP: Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun2008; 369: 1114–1119.
21.
PanticMZimmermannSEl DalyH: Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells. Oncogene2006; 25: 4413–4420.
22.
JagadeeshSBanerjeePP: Telomerase reverse transcriptase regulates the expression of a key cell cycle regulator, cyclin D1. Biochem Biophys Res Commun2006; 347: 774–780.
23.
ItoYYoshidaHKakudoK: Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology2006; 38: 421–425.
24.
TanHYeKWangZ: Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol2008; 38: 528–533.
25.
MitselouAIoachimEPeschosD: E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol2007; 29: 54–60.
26.
van der LaanBFFreemanJLAsaSL: Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid1995; 5: 67–73.
27.
ScognamiglioTHyjekEKaoJ: Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol2006; 126: 700–708.
28.
ItoYYoshidaHTomodaC: HBME-1 expression in follicular tumor of the thyroid: An investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res2005; 25: 179–182.
